EVAX Evaxion A/S IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1828253 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY125.1%
TTM net income YoY27.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-122.7%
Net margin-102.4%
FCF margin-88.2%
EBITDA margin—
Returns
ROE-100.2%
ROA-37.7%
ROIC (approx.)—
Asset turnover0.37x
Leverage & solvency
Liabilities / assets40.0%
Debt / equity0.32x
Current ratio5.85x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $7.53M | $3.34M |
| R&D expense | $9.97M | $10.46M |
| SG&A expense | $6.79M | $7.62M |
| Operating income | -$9.23M | -$14.73M |
| Interest expense | $0 | $0 |
| Pretax income | -$8.62M | -$11.36M |
| Income tax | -$908,000 | -$788,000 |
| Net income | -$7.71M | -$10.57M |
| EPS (basic) | -0.02 | -0.20 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $23.23M | $5.95M |
| Current assets | $24.90M | $8.77M |
| PP&E, netmay include right-of-use assets (IFRS) | $3.32M | $3.51M |
| Intangibles | $0 | $0 |
| Total assets | $28.41M | $12.48M |
| Current liabilities | $4.26M | $4.37M |
| Short-term debt | $190,000 | $159,000 |
| Long-term debt | $5.35M | $8.01M |
| Total debt | $5.54M | $8.17M |
| Total liabilities | $11.37M | $14.14M |
| Shareholders' equity | $17.04M | -$1.65M |
| Net debt | -$17.70M | $2.21M |
| Shares outstanding | 417.01M | — |
| Cash flow statement | ||
| Operating cash flow | -$6.62M | -$12.94M |
| Capital expenditure | $11,000 | $0 |
| Free cash flow | -$6.64M | -$12.94M |
| Investing cash flow | -$14,000 | -$3,000 |
| Financing cash flow | $22.41M | $13.13M |
| Stock-based compensation | $307,000 | $357,000 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.